Antiangiogenic agents after first line and sorafenib plus

HIGHLIGHTS

• who: Top from the Italy Medical Oncology Department, University Campus Bio-Medico, Via Álvaro del Portillo, Rome, Italy have published the research work: Antiangiogenic agents after first line and sorafenib plus, in the Journal: (JOURNAL)
• what: A meta-analysis that included all four studies show that TACE plus sorafenib may have superiority of TACE only in terms of time to progression (HR=0.77, P=0.005) but not for OS (HR=0.97, P=0.828), ORR (RR=1.20, P=0.257) and DCR (RR=1.04, P=0.568) .
• how . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.